239 / 258
F
eng
et al
.:
J
ournal of
AOAC I
nternational
V
ol
.
100, N
o
.
2, 2017
521
Acknowledgments
We thank Hongxu Chen and Jianhua Wu (AB Sciex)
for providing the PA 800 Plus instrument and instrument
maintenance, Chao Wu (Hilmar Ingredients) for helping
us understand the meaning of split peaks for infant
formula proteins, Longfei Wang (Nestlé Food Safety
Institute, Beijing) for providing the laboratory facilities, and
Wyeth Nutrition Suzhou for supplying pilot-scale placebo
infant formula samples and samples with different protein
ingredients.
References
(1)
Official Methods of Analysis
(2012) 19th Ed., AOAC
INTERNATIONAL, Rockville, MD, Appendix L: AOAC
Recommended Guidelines for Stakeholder Panel on Infant
Formula and Adult Nutritionals (SPIFAN) Single-Laboratory
Validation
(2) (January 2014) Application Guide, PA 800 Plus Pharmaceutical
Analysis System, Part No. A51970AD, Beckman Coulter, Inc.,
Fullerton, CA
(3) Rudloff, S., & Lönnerdal, B.
(1992) J. Pediatr. Gastroenterol. Nutr. 15 , 25–33. doi:10.1097/00005176-199207000-00005
(4) Walstra, P., Wouters, J.T.M., & Geurts, T.J. (2005)
Dairy Science and Technology
, 2nd Ed., CRC Press,
Boca Raton, FL
(5) Koletzko, B., Baker, S., Cleghorn, G., Neto, U.F.,
Gopalan, S., Hernell, O., Hock, Q.S., Jirapinyo, P.,
Lonnerdal, B., Pencharz, P., Pzyrembel, H., Ramirez-
Mayans, J., Shamir, R., Turck, D., Yamashiro, Y., & Zong-Yi,
D.
(2005) J. Ped. Gastroenterol. Nutr. 41 , 584–599,Table 3
239